Talaris Therapeutics Inc (TALS)

(10% Negative) TALARIS THERAPEUTICS, INC. (TALS) Announces Delay in reflected Development Timeline Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Fate Therapeutics Inc (FATE)

(10% Negative) FATE THERAPEUTICS, INC. (FATE) Announces Delay in innovation Trials for Solid Tumors San Diego Due to Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment